Novo Nordisk's CagriSema Trial Results Fall Short, Market Reacts

Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's market shares. The trial showed a 13.7% weight loss, which fell short of expectations. Investors and analysts express concern over the drug's market potential.

Novo Nordisk's recent trial results for their obesity drug candidate, CagriSema, have sparked concerns among investors. Intended as a successor to the successful Wegovy, CagriSema aimed to surpass Eli Lilly's Mounjaro. However, findings showed a 13.7% weight reduction, not enough to outpace Mounjaro's influence in the market.

Investors, like Markus Manns, express disappointment in Novo's inflated expectations for CagriSema. The trial's flexible protocol allowed dosing variations, and although weight loss could reach 15.7% with full adherence, industry analysts expected higher outcomes to declare the drug a success.

The trial's outcome impacted Novo's stock, with shares down over 6%. In contrast, Lilly's Zepbound, known as Mounjaro, now outpaces Wegovy in prescriptions. This competitive edge is evident as Novo's shares decline while Lilly's gain. Analysts criticize the omission of A1C level data, which remains awaited.